🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Anthem Inc reports 8% rise in quarterly profit

Published 07/24/2019, 08:28 AM
© Reuters. The office building of health insurer Anthem is seen in Los Angeles, California
ELV
-

By Tamara Mathias

(Reuters) - Anthem Inc (N:ANTM) shares fell as much as 4% on Wednesday after the U.S. health insurer missed Wall Street expectations for a key medical cost gauge as a result of higher costs of selling Medicaid health plans for low-income customers.

Anthem reported a 10.2% fall in operating profit from its unit which sells government health plans, in the quarter, saying the decline was driven by continued elevated medical cost trends in Medicaid in some states.

Concerns about medical costs took the shine off the group's better-than-expected second-quarter earnings and increased full year forecast for adjusted earnings, which in part reflected the successful launch of its new pharmacy benefits business.

As regulatory uncertainties about the health insurance sector persist ahead of the 2020 U.S. presidential elections, Anthem has doubled down on diversifying its business and in May started shifting members to the new pharmacy benefits unit, IngenioRx.

The Indianapolis, Indiana-based company raised its 2019 adjusted net income forecast to over $19.30 per share from a prior estimate of greater than $19.20.

"We now expect IngenioRx to achieve the upper end of our $0.70 - $0.90 guidance," Chief Executive Officer Gail Boudreaux said in a statement, referring to 2019 earnings per share contribution from the unit.

Anthem's benefit expense ratio — the percentage of premiums paid for medical services — worsened to 86.7% from 83.4% a year earlier. Analysts on average expected 86%, according to IBES data from Refinitiv. A lower benefit expense ratio is better for health insurers.

Anthem updated its 2019 forecast for the ratio to 86.2% to 86.5%, from an earlier 85.9% to 86.5% range.

Although the progress of IngenioRx is encouraging for long-term outlook, the focus is likely to remain on the benefits expense ratio underperformance and continued elevated medical costs in certain Medicaid states, Evercore ISI analyst Michael Newshel said.

Anthem shares rose 2% after the results, but quickly gave up all the gains and were down 3.5% at $292 before the bell.

On Tuesday, its rival Centene Corp (N:CNC) warned of higher costs than previously expected this year, while UnitedHealth Group (N:UNH), the largest U.S. health insurer, also missed estimates for medical costs in the second quarter.

Anthem's net income rose 8% to $1.14 billion, or $4.36 per share, in the quarter ended June 30.

Excluding items, the company earned $4.64 per share, ahead of the average analyst estimate of $4.61.

Anthem raised its 2019 operating revenue forecast to about $102 billion, up from an earlier estimate of about $100 billion.

© Reuters. The office building of health insurer Anthem is seen in Los Angeles, California

Total operating revenue rose about 11% to $25.18 billion, beating Wall Street targets of $24.87 billion, it said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.